Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613802

— · D

c6b69bc5-3950-527f-bd0b-7a0926bf7ea4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.480
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
  • MITOTIC_SPINDLE+0.470
  • INTERFERON_GAMMA_RESPONSE+0.420
  • UV_RESPONSE_DN+0.380
  • G2M_CHECKPOINT+0.360
  • ALLOGRAFT_REJECTION+0.340
  • TGF_BETA_SIGNALING+0.330
  • IL6_JAK_STAT3_SIGNALING+0.320
  • NOTCH_SIGNALING+0.280

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.410
  • FATTY_ACID_METABOLISM-0.320
  • PEROXISOME-0.300
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
  • ADIPOGENESIS-0.260
  • ESTROGEN_RESPONSE_EARLY-0.250
  • BILE_ACID_METABOLISM-0.230
  • GLYCOLYSIS-0.230
  • MYC_TARGETS_V2-0.230
  • XENOBIOTIC_METABOLISM-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1198b23eb-5efa-4c7e-84f6-96976474de0b
melanoma-umap@29
——0.887
257f2cc66-9163-4e07-93f8-d5a2158e7125
melanoma-umap@29
——0.874
3TCGA-A2-A0SX-01A-12R-A084-07
breast-umap@18
—D0.874
46a43f966-cb2b-47ee-b0f4-c269707daa88
melanoma-umap@29
——0.874
5SRR8518214
breast-umap@18
—D0.864
6TCGA-CR-7382-01A-11R-2132-07
head-neck@1
——0.862
7TCGA-85-8287-01A-11R-2296-07
lung-landscapes@6
—cohortSQ10.851
8TCGA-55-6978-01A-11R-1949-07
lung-landscapes@6
—cohortA10.849
9TCGA-44-7662-01A-11R-2066-07
lung-landscapes@6
—cohortA10.842
10SRR4296078
lung-landscapes@6
—cohortSQ10.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.480Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.470Inavolisib— uncovered
MITOTIC_SPINDLE0.470Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.420Idelalisib— uncovered
UV_RESPONSE_DN0.380Inavolisib— uncovered
G2M_CHECKPOINT0.360Inavolisib— uncovered
ALLOGRAFT_REJECTION0.340Idelalisib— uncovered
TGF_BETA_SIGNALING0.330Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.320Inavolisib— uncovered
NOTCH_SIGNALING0.280Inavolisib— uncovered
COMPLEMENT0.270Inavolisib— uncovered
APICAL_JUNCTION0.260Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.260Idelalisib— uncovered
E2F_TARGETS0.240Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.220Inavolisib— uncovered
HEDGEHOG_SIGNALING0.210Inavolisib— uncovered
KRAS_SIGNALING_UP0.180Inavolisib— uncovered
IL2_STAT5_SIGNALING0.170Idelalisib— uncovered
COAGULATION0.160Binimetinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.150Inavolisib— uncovered